Aliso Viejo, CA, May 5, 2009 – Ambry Genetics announces the implementation of Comparative Genomic Hybridization (CGH) using oligonucleotide arrays through a partnership with Baylor College of Medicine. Large chromosomal abnormalities that are associated with over 270 genetic syndromes can be easily identified via analysis of each 105K whole genome and mitochondrial array. The partnership…

Aliso Viejo, CA, April 29, 2009 – Ambry Genetics announced today that it has successfully completed Illumina CSPro™ Certification for Genome Analyzer (GA) Sequencing, gaining entry to an elite group of Illumina Certified Service Providers globally. Illumina Inc., a San Diego-based company, provides leading-edge genetic analysis tools to genomics centers worldwide. The Illumina CSPro™ is…

Aliso Viejo, CA, March 20, 2009 – Ambry Genetics today announced capabilities of performing sequence capture for the Illumina® or Roche® Next Generation Sequencing platforms. Customers will have the option of choosing either custom 385K or pre-designed 2.1M high density arrays available through Roche® NimbleGen. Sequencing can be done in-house at Ambry on the Illumina®…

Aliso Viejo, CA, April 22, 2008 – Ambry Genetics is pleased to announce the acquisition of an Illumina Genome Analyzer. This technology has the capabilities to greatly reduce time and costs of gene sequencing. This tool will allow Ambry to capitalize on its leadership in clinical genetic testing with entry into the growing field of…

Aliso Viejo, CA, January 28, 2008 – Ambry Genetics, a recognized leader in comprehensive clinical genetic testing, has created a new division to support Pharmaceutical Research, Clinical Research Organizations (CROs) and Clinical Trials. The role that genetics is taking in drug development and Clinical Trials is expanding as new technologies enable rapid analysis of genetic…

Aliso Viejo, CA, August 13, 2007 – Ambry Genetics, a leader in comprehensive genetic testing, has introduced the first clinically-available genetic test for mutations causing Idiopathic Pulmonary Fibrosis (IPF), an incurable lung disease affecting approximately 128,000 people in the U.S. Previously, all causes of IPF were unknown. Recent research published by groups based at Johns…

Aliso Viejo, CA, April 28, 2007 – Specialists who treat children with Cystic Fibrosis (CF) have realized what we surfers already knew – that the ocean cleans out our system. Patients in Australia reported feeling significantly better after surfing. Medical scientists and physicians have turned this observation into a new medical treatment for CF called…

Aliso Viejo, CA, December 7, 2006 – Ambry Genetics, a recognized leader in comprehensive genetic testing, has expanded its pulmonary genetic test menu to diagnose defects in ABCA3. The gene ABCA3 is a critical component in prevention of severe neonatal respiratory distress and pediatric Interstitial Lung Diseases. The ABCA3 gene has a key role in…

Ambry Genetics, a leader in genetic testing, has introduced highly sensitive tests for detection of mutations causing two devastating diseases of childhood. Tay-Sachs Disease and Canavan Diseases are both severe, progressive diseases that disable the nervous system and cause early death. Due to an especially high carrier rate in certain populations, medical professionals have for…

Samples from patients that prove negative for DeltaF508 will be automatically routed to the Ambry Test: CF AMPLIFIED® for the most comprehensive analysis available. With a detection rate of approximately 99%, no other test can identify more mutations than the Ambry Test: CF AMPLIFIED. Ambry Genetics President & CEO, Charles L. M. Dunlop, explains: “508…